Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, showing that each pending matter is being handled by a different official. Despite the involvement of multiple examiners, all activity is concentrated within 1 distinct art unit.
GONZALEZ, LUISALBERTO is identified as the busiest examiner for the portfolio, currently overseeing 1 pending office action. With 2 pending office actions and 2 distinct examiners, the company prosecution is spread across different individuals while remaining within a single technical group at the patent office. This individual is one of the officials currently reviewing the company work.
For practitioners, this distribution means that the 2 pending office actions are being reviewed by separate officials. However, the use of only 1 distinct art unit suggests that the subject matter of both actions is technically similar. This profile requires managing different examiner relationships within the same specialized division of the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALEZ, LUISALBERTO | 1 | 59.4% | +47.2% |
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258455 | 1,8-CINEOLE CONTAINING COMPOSITION FOR THERAPEUTIC USE | GONZALEZ, LUISALBERTO | 14d |
| 18252962 | NEW THERAPY CONCEPT FOR THE TREATMENT OF CORONA INFECTIONS, ESPECIALLY COVID-19 INFECTIONS | KIFLE, BRUCK | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18258455 | 1,8-CINEOLE CONTAINING COMPOSITION FOR THERAPEUTIC USE | GONZALEZ, LUISALBERTO | 1624 | §112 | Final Rejection | 14d | Pending | Jun 20, 2023 |
| 18252962 | NEW THERAPY CONCEPT FOR THE TREATMENT OF CORONA INFECTIONS, ESPECIALLY COVID-19 INFECTIONS | KIFLE, BRUCK | 1624 | §103 | Non-Final OA | — | Pending | May 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial